Evidence map›Paper›PMID 42412178›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Real-world evaluation of [

Muammer Misirci, Florian Rosar, Fadi Khreish, Caroline Burgard, Arne Blickle, Mark Bartholomä, Stephan Maus, Moritz B Bastian, Tilman Speicher, Sven Petto and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Organ and tumor dosimetry of [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Muammer MisirciDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Florian RosarDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Fadi KhreishDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Caroline BurgardDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Arne BlickleDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Mark BartholomäDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Stephan MausDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Moritz B BastianDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Tilman SpeicherDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Sven PettoDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Sebastian GanzDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Andrea Schaefer-SchulerDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany.
Samer EzziddinDepartment of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, Homburg, D-66421, Germany. samer.ezziddin@uks.eu.ORCID http://orcid.org/0000-0003-4110-3375

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEvaluating efficacy and safety of individualized [

methodsPer‑cycle activities of [

resultsMedian administered activity was 7.1 GBq per cycle (range 2.7-11.6 GBq) and cumulative activity 22.3 GBq (range 2.7-77.8 GBq), while patients received a median of 3 cycles within a 6-week interval. After a median follow‑up of 15.9 months (95%CI: 11.2-20.5 months), median PSA‑PFS was 5.1 months (95% CI: 4.0-6.2 months), and median OS 14.5 months (95% CI: 11.4-17.7 months). PSA declined after the first cycle in 63.9% of patients; PSA reduction ≥ 50% occurred in 51.5%. Shortened PSA‑PFS was associated with visceral metastasis (p = 0.001) and ALP ≥ 220 U/L (p = 0.004). Shortened OS was associated with visceral metastasis (p = 0.009), ALP ≥ 220 U/L (p = 0.001), age ≤ 65 years (p = 0.034), hemoglobin < 9 g/dL (p = 0.006), and early biochemical progressive disease after 1-2 courses (p < 0.001). Newly occurring or worsening hematologic or renal impairments ≥ CTCAE °3 were uncommon.

conclusionIn conclusion, the retrospective real-world analysis suggests that individualized, dose-adapted

Indexed as

Bridged-Ring CompoundsDipeptidesHeterocyclic Compounds, 1-RingLutetiumPrecision MedicineProstatic Neoplasms, Castration-ResistantSafetyAgedAged, 80 and overCohort StudiesFeasibility StudiesHumansMaleMiddle AgedProstate-Specific AntigenRadioisotopesBridged-Ring CompoundsDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617RadioisotopestaxaneTaxoids177Lu-PSMAOutcome predictorsPost-taxane mCRPCPSMA radioligand therapyReal-world analysis

Identifiers

PMID42412178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.